Novo Nordisk Shares Face Mounting Pressure Amid Profit Warning and Pricing Shift

Novo Nordisk issues profit warning after U.S. price cuts and a failed trial. The firm is acquiring assets to diversify beyond its GLP-1 blockbusters as shares tumble.

The pharmaceutical giant Novo Nordisk, once a darling of European equity markets, is navigating turbulent waters. A confluence of factors—including an unexpected profit warning, enforced price reductions in the United States, and a clinical trial setback—has rattled investor confidence. The company's new chief executive now confronts the formidable challenge of reversing a steep decline that has extended a difficult period for the firm.

Strategic Acquisitions and New Approvals

In a strategic pivot to reduce its heavy reliance on current GLP-1 blockbuster drugs, Novo Nordisk is pursuing expansion. The company secured promising candidates for treating metabolic dysfunction-associated steatohepatitis (MASH) through its acquisition of Akero Therapeutics for $5.2 billion. In a related development, the active ingredient semaglutide (marketed as Wegovy) recently received U.S. approval for this very liver disease indication. This milestone is viewed as crucial for diversifying the drug's application beyond weight management alone.

Analyst Divisions Following Clinical Trial Data

Beyond pricing pressures, the failure of the late-stage REDEFINE-4 clinical trial has added to the company's woes. The combination drug CagriSema did not demonstrate superiority against a competing product from Eli Lilly. This development has sparked divergent interpretations among market experts.

Deutsche Bank responded to the disappointment by slashing its price target for Novo Nordisk shares by 31% and downgrading its rating to "Hold." In contrast, analysts at Morgan Stanley adopted a more balanced view, upgrading the stock to "Equal-weight." Their rationale posits that medium-term risks, along with the planned halving of U.S. list prices by 2027, are now fully reflected in the current share valuation. They further noted that the fundamental valuation has become more attractive following the significant price correction.

Gloomy Forecasts Driven by U.S. Pricing Agreement

The immediate source of market pessimism stems from a rare event: management's projection of a 5% to 13% decline in both revenue and operating profit for 2026. A primary driver of this forecast is a pricing agreement concluded with the U.S. government in November of last year. Through the direct distribution channel "TrumpRx," prices for the top-selling drugs Wegovy and Ozempic have plummeted from over $1,000 to just $350 per month.

Company leadership and financial analysts alike characterize this dynamic as unprecedented headwinds that will substantially compress margins in this critical market. The strain is evident in the share price performance. Trading at a current level of €33.17, the equity has shed nearly 26% of its value since the start of the year and now sits more than 55% below its 52-week high.

A Period of Fundamental Transition

Facing regulatory pressure in the U.S., intensified competition, and an ongoing leadership transition, Novo Nordisk is entrenched in a fundamental reshaping phase. The era of explosive growth that briefly crowned it Europe's most valuable company in 2024 appears to be over, at least for now. Investors await further details on the strategic recalibration, the progress of a $2.37 billion share buyback program, and the approach to managing declining revenue. Management is expected to provide this outlook at the upcoming annual general meeting scheduled for March 26, 2026.